1404 related articles for article (PubMed ID: 11294039)
1. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological modulation of the effects induced by ketamine at subanesthetic doses].
Mechri A; Micallef J; Blin O; Saoud M; Daléry J; Gaha L
Therapie; 2001; 56(5):617-22. PubMed ID: 11806303
[TBL] [Abstract][Full Text] [Related]
3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
4. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
Doreulee N; Alania M; Mitaishvili E; Chikovani M; Chkhartishvili B
Georgian Med News; 2009 Dec; (177):59-65. PubMed ID: 20090156
[TBL] [Abstract][Full Text] [Related]
5. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
6. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.
Krystal JH; Perry EB; Gueorguieva R; Belger A; Madonick SH; Abi-Dargham A; Cooper TB; Macdougall L; Abi-Saab W; D'Souza DC
Arch Gen Psychiatry; 2005 Sep; 62(9):985-94. PubMed ID: 16143730
[TBL] [Abstract][Full Text] [Related]
7. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
[TBL] [Abstract][Full Text] [Related]
8. The acute effects of NMDA antagonism: from the rodent to the human brain.
Gunduz-Bruce H
Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
[TBL] [Abstract][Full Text] [Related]
9. Glutamatergic aspects of schizophrenia.
Tamminga C
Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
[TBL] [Abstract][Full Text] [Related]
10. N-methyl-D-aspartate receptor in working memory impairments in schizophrenia: event-related potential study of late stage of working memory process.
Ahn KH; Youn T; Cho SS; Ha TH; Ha KS; Kim MS; Kwon JS
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):993-9. PubMed ID: 14499316
[TBL] [Abstract][Full Text] [Related]
11. [Glutamatergic hypothesis of schizophrenia: psychoses induced by phencyclidine and cortical-subcortical imbalance].
Krebs MO
Encephale; 1995; 21(5):581-8. PubMed ID: 8529568
[TBL] [Abstract][Full Text] [Related]
12. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
Maćkowiak M; Czyrak A; Wedzony K
Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
[TBL] [Abstract][Full Text] [Related]
13. The NMDA antagonist model for schizophrenia: promise and pitfalls.
Abi-Saab WM; D'Souza DC; Moghaddam B; Krystal JH
Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():104-9. PubMed ID: 9754841
[TBL] [Abstract][Full Text] [Related]
14. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?
Farber NB; Wozniak DF; Price MT; Labruyere J; Huss J; St Peter H; Olney JW
Biol Psychiatry; 1995 Dec; 38(12):788-96. PubMed ID: 8750036
[TBL] [Abstract][Full Text] [Related]
15. Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency.
Nagels A; Kirner-Veselinovic A; Krach S; Kircher T
Neuroimage; 2011 Jan; 54(2):1307-14. PubMed ID: 20727411
[TBL] [Abstract][Full Text] [Related]
16. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Krystal JH; Karper LP; Seibyl JP; Freeman GK; Delaney R; Bremner JD; Heninger GR; Bowers MB; Charney DS
Arch Gen Psychiatry; 1994 Mar; 51(3):199-214. PubMed ID: 8122957
[TBL] [Abstract][Full Text] [Related]
17. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
Bubeníková-Valesová V; Horácek J; Vrajová M; Höschl C
Neurosci Biobehav Rev; 2008 Jul; 32(5):1014-23. PubMed ID: 18471877
[TBL] [Abstract][Full Text] [Related]
18. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
Large CH
J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
[TBL] [Abstract][Full Text] [Related]
19. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
Heresco-Levy U
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
[TBL] [Abstract][Full Text] [Related]
20. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
Hashimoto K; Iyo M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
